Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease

被引：1
|
作者：
Aldrich, Sarah [1 ]
Ashjian, Emily [2 ]
机构：
[1] Univ Toledo, Coll Pharm & Pharmaceut Sci, 2801 W Bancroft St, Toledo, OH 43606 USA
[2] Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA
来源：
NURSE PRACTITIONER | 2019年 / 44卷 / 03期
关键词：
chronic kidney disease; diabetes; dialysis; dulaglutide; end-stage renal disease; exenatide; glucagon-like peptide-1 receptor agonist; liraglutide; lixisenatide; semaglutide; type 2 diabetes mellitus; CARDIOVASCULAR OUTCOMES; TYPE-2; RISK; EXENATIDE; SAFETY; PHARMACOKINETICS; LIXISENATIDE; TOLERABILITY; DULAGLUTIDE; MORTALITY;
D O I：
10.1097/01.NPR.0000553396.65976.bb
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Diabetes mellitus is the leading cause of chronic kidney disease (CKD) in the US. An increasing number of glucagon-like peptide-1 receptor agonists are available for diabetes management. Differences between medications in this class, as well as limited data on patients with CKD, underscore the importance of a patient-centered approach to care.
引用
收藏
页码：20 / 28
页数：9
相关论文
共 50 条
  • [1] GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
    Neumiller, Joshua J.
    Alicic, Radica Z.
    Tuttle, Katherine R.
    KIDNEY AND DIALYSIS, 2022, 2 (03): : 386 - 398
  • [2] Treatment of Type 2 Diabetes mellitus (T2DM): Can GLP-1 Receptor Agonists fill in the gaps?
    Sharma, Smriti
    Bhatia, Vinayak
    CHEMICAL BIOLOGY LETTERS, 2020, 7 (04): : 215 - 224
  • [3] GLP-1 Receptor Agonists in Diabetic Kidney Disease
    Michos, Erin D.
    Tuttle, Katherine R.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (10): : 1578 - 1580
  • [4] EFFICACY AND SAFETY OF COTADUTIDE, A DUAL GLP1-GLUCAGON RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND T2DM
    Selvarajah, Viknesh
    Robertson, Darren
    Hansen, Lars
    Jermutus, Lutz
    Smith, Kirsten
    Frickleton, Celeste
    Coggi, Angela
    Sanchez, Jose
    Chang, Yi-Ting
    Parker, Victoria
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I87 - I87
  • [5] Comparative safety of GLP-1 agents in T2DM
    Reactions Weekly, 2013, 1450 (1) : 4 - 4
  • [6] GLP-1 receptor agonists modulate blood glucose levels in T2DM by affecting Faecalibacterium prausnitzii abundance in the intestine
    Liang, Lei
    Rao, Elizabeth
    Zhang, Xuxiang
    Wu, Bin
    Su, Xiaoyun
    Chen, Lin
    Nie, Rong
    Nian, Xin
    MEDICINE, 2023, 102 (35) : E34978
  • [7] GLP-1 Receptor Agonists and Kidney Protection
    Greco, Eulalia Valentina
    Russo, Giuseppina
    Giandalia, Annalisa
    Viazzi, Francesca
    Pontremoli, Roberto
    De Cosmo, Salvatore
    MEDICINA-LITHUANIA, 2019, 55 (06):
  • [8] Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD
    Parker, Victoria E.
    Hoang, Thuong
    Schlichthaar, Heike
    Gibb, Fraser W.
    Wenzel, Barbara
    Posch, Maximilian G.
    Chang, Yi-Ting
    Petrone, Marcella
    Hansen, Lars
    Ambery, Philip
    Heerspink, Hiddo L.
    Mccrimmon, Rory J.
    Jermutus, Lutz
    DIABETES, 2021, 70
  • [9] First oral GLP-1 treatment for T2DM is approved
    不详
    NURSE PRACTITIONER, 2020, 45 (01): : 56 - 56
  • [10] Real-World Persistence with GLP-1 RA Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) and Advanced Chronic Kidney Disease (CKD)
    Sidra, Fnu
    Xie, Donglu
    Agarwal, Shubham
    Lingvay, Ildiko
    DIABETES, 2023, 72
12345